BPG is committed to discovery and dissemination of knowledge
Meta-Analysis
©The Author(s) 2024.
World J Virol. Mar 25, 2024; 13(1): 91457
Published online Mar 25, 2024. doi: 10.5501/wjv.v13.i1.91457
Table 3 Baseline laboratory parameters and hospital course
Parameter of interest
Frequency (%)
Hematocrit, median 42.60 (IQR 15.15)
Total leucocyte count (per µL), median 5800 (IQR 5800)
Platelet count (per µL), median 25500 (IQR 28250)
AST (U/L), median 4625 (IQR 11902.5)
ALT (U/L), median 3100 (IQR 2607)
AST/ALT ratio, median 2.45 (IQR 1.75)
Alkaline phosphatase (IU/L), median 191 (IQR 117)
Total bilirubin (mg/dL), median 5.5 (IQR 5.63)
Direct bilirubin (mg/dL), median 2.55 (IQR 2.75)
INR, median 2.13 (IQR 1.79)
Albumin (g/L), median 2.85 (IQR 0.48)
Creatinine (mg/dL), median 1.63 (IQR 2.12)
MELD score, median 27.5 (IQR 5)
Days of ICU stay, median 6 (IQR 2)
Specific therapies
N-acetyl cysteine 6 (31.6)
Types of organ support
Vasopressors 8 (42.1)
Renal replacement therapy 6 (31.6)
Ventilation6 (31.6)
MARS1 (5.3)
Organ failure 14 (73.7)
Neurological10 (52.6)
Cardiac8 (42.1)
Renal7 (36.8)
Respiratory
Complications
Hepatic encephalopathy13 (68.4)
Bleedings3 (15.8)
DVT1 (5.3)
Liver transplantation2 (10.5)
Death1 (5.3)


Write to the Help Desk